期刊
CLINICAL IMMUNOLOGY
卷 222, 期 -, 页码 -出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2020.108574
关键词
Eosinophilic granulomatosis with polyangiitis; EGPA; Benralizumab; Sepsis; Churg-Strauss vasculitis
类别
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a small-vessels vasculitis associated with ANCA, characterized by hypereosinophilia and eosinophilic asthma. In cases of life-threatening organ involvement, particularly cardiac and central nervous system (CNS), immediate immunosuppression is required. Antibiotic therapy combined with Benralizumab can be a potential therapeutic option for active EGPA with eosinophil-mediated pathologies in severely ill patients.
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is an ANCA-associated small-vessels vasculitis characterized by hypereosinophilia and eosinophilic asthma. EGPA with life-threatening organ involvement, particularly cardiac and central nervous system (CNS), is a medical emergency requiring immediate immunosuppression. We describe a 58-year-old patient with a history of chronic rhinosinusitis and eosinophilic asthma, who presented with fever, hypereosinophilia and systemic inflammation. Diagnostic workup identified a cardiac mass, CNS vasculitis, CNS embolization and Staphylococcus aureus in blood cultures. Due to rapid normalization of blood cultures, the intracardiac mass was not considered as primarily infective. Active EGPA with cardiac and CNS involvement complicated by a secondary S. aureus sepsis was diagnosed. In order to not negatively impact antibacterial immunity in active EGPA, antibiotic therapy was combined with Benralizumab, which was well tolerated and EGPA resolved rapidly. Benralizumab could serve as a therapeutic option for eosinophil-mediated pathologies in severely ill patients where immunosuppressives are initially contraindicated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据